Drug Profile

CLX GI 03

Alternative Names: CLX-103; CLX-GI-03

Latest Information Update: 28 Sep 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cellix Bio
Class Aminosalicylic acids; Anti-inflammatories; Drug conjugates; Eicosanoids; Omega 3 fatty acids; Small molecules
Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Sep 2024 No recent reports of development identified for preclinical development in Ulcerative-colitis in India
22 Sep 2022 CLX GI 03 is still in preclinical phase for Ulcerative Colitis in India (Cellix Bio pipeline, September 2022).
28 Mar 2022 No recent reports of development identified for preclinical development in Ulcerative-colitis in India

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com